中国糖尿病杂志
中國糖尿病雜誌
중국당뇨병잡지
CHINESE JOURNAL OF DIABETES
2010年
11期
806-808
,共3页
代谢综合征%脂联素%胰岛素抵抗%罗格列酮
代謝綜閤徵%脂聯素%胰島素牴抗%囉格列酮
대사종합정%지련소%이도소저항%라격렬동
Metabolic syndrome%Adiponectin% Insulin resistance%Rosiglitazone
目的 观察无糖尿病的代谢综合征(MS)患者血清脂联素(APN)水平,及其与胰岛素抵抗(IR)的相关性,了解罗格列酮(RGZ)对APN和IR的影响.方法 92例无糖尿病的MS患者,随机分为A组(n=40)仅予常规治疗,B组(n=52)常规治疗加RGZ口服.用药前及用药8周后,酶联免疫吸附法测定血清APN,计算IR指数(HOMA-IR)、胰岛素敏感性指数(ISI),并与30名健康人对照.结果 (1)MS组APN水平明显低于健康对照组[(1.15±0.81)mg/L铘(4.81士1.20)mg/L,P<0.01].(2)MS组APN水平与HOMA-IR负相关(P<0.01),与ISI正相关(P<0.01).(3)B组治疗后血清APN升高[从(0.89±0.73)mg/L升至(2.52±1.37)mg/L,P<0.01],HOMA-IR降低(从1.50±0.45降至0.99±0.35,P<0.01),ISI升高(从-4.61±0.45升至-4.10±0.36,P<0.01).结论 无糖尿病的MS患者血清APN水平降低,与IR相关.RGZ可提高APN水平,改善其胰岛素敏感性.
目的 觀察無糖尿病的代謝綜閤徵(MS)患者血清脂聯素(APN)水平,及其與胰島素牴抗(IR)的相關性,瞭解囉格列酮(RGZ)對APN和IR的影響.方法 92例無糖尿病的MS患者,隨機分為A組(n=40)僅予常規治療,B組(n=52)常規治療加RGZ口服.用藥前及用藥8週後,酶聯免疫吸附法測定血清APN,計算IR指數(HOMA-IR)、胰島素敏感性指數(ISI),併與30名健康人對照.結果 (1)MS組APN水平明顯低于健康對照組[(1.15±0.81)mg/L铘(4.81士1.20)mg/L,P<0.01].(2)MS組APN水平與HOMA-IR負相關(P<0.01),與ISI正相關(P<0.01).(3)B組治療後血清APN升高[從(0.89±0.73)mg/L升至(2.52±1.37)mg/L,P<0.01],HOMA-IR降低(從1.50±0.45降至0.99±0.35,P<0.01),ISI升高(從-4.61±0.45升至-4.10±0.36,P<0.01).結論 無糖尿病的MS患者血清APN水平降低,與IR相關.RGZ可提高APN水平,改善其胰島素敏感性.
목적 관찰무당뇨병적대사종합정(MS)환자혈청지련소(APN)수평,급기여이도소저항(IR)적상관성,료해라격렬동(RGZ)대APN화IR적영향.방법 92례무당뇨병적MS환자,수궤분위A조(n=40)부여상규치료,B조(n=52)상규치료가RGZ구복.용약전급용약8주후,매련면역흡부법측정혈청APN,계산IR지수(HOMA-IR)、이도소민감성지수(ISI),병여30명건강인대조.결과 (1)MS조APN수평명현저우건강대조조[(1.15±0.81)mg/L야(4.81사1.20)mg/L,P<0.01].(2)MS조APN수평여HOMA-IR부상관(P<0.01),여ISI정상관(P<0.01).(3)B조치료후혈청APN승고[종(0.89±0.73)mg/L승지(2.52±1.37)mg/L,P<0.01],HOMA-IR강저(종1.50±0.45강지0.99±0.35,P<0.01),ISI승고(종-4.61±0.45승지-4.10±0.36,P<0.01).결론 무당뇨병적MS환자혈청APN수평강저,여IR상관.RGZ가제고APN수평,개선기이도소민감성.
Objective To study a serum adiponectin level and a relationship between serum adiponectin and insulin resistance in metabolic syndrome (MS) patients without diabetes and to investigate its influence of rosiglitazone(RGZ). Methods Besides control group(n=30),92 MS patients without diabetes were divided randomly into A group(n=40,routine treatment ) and B group(n=52,plus RGZ). The serum adiponectin was measured by enzyme linked immunosorbent assay,HOMA-IR,and insulin sensitivity index(ISI) were calculated. Results The serum adiponectin was significantly lower in metabolic syndrome group than in normal control group［（1.15±0.81)mg/L vs (4.81±1.20 )mg/L, P<0.01］.The serum adiponectin level was negatively correlated with HOMA-IR（P<0.01）, and positively correlated with ISI（P<0.01）. There was a significant increase in serum adiponectin ［(2.52 ±1.37) mg/L vs （0.89±0.73)mg/L，P<0.01］ and ISI（-4.61±0.45 vs -4.61±0.45，P<0.01）, a significant decrease in HOMA-IR（0.99±0.35 vs 1.50±0.45，P<0.01）in B group versus A group. Conclusions The serum adiponectin in MS cases without diabetes is significantly decreased，negatively correlated with HOMA-IR. There is a significant increase in serum adiponectin and ISI, a significant decrease in HOMA-IR after RGZ treatment in MS cases without diabetes.
